Inhibikase Therapeutics

Inhibikase Therapeutics, Inc. provides infectious disease treatments. It develops small molecule platform for treating both bacterial and viral infectious diseases. It operates through RAMP™ Drug Innovation Engine technology. The company was founded by Milton H. Werner in September 2008 and is headquartered in Atlanta, GA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inhibikase Therapeutics advances trials amidst safety concerns and financial stability

Inhibikase Therapeutics made progress in trials but faces safety concerns and financial challenges.
Opportunities lie in advancing Phase III plans and clinical development for potential market growth.
The company's near-term milestones and financial stability are key areas to watch for future performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in developing protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The company was founded by Milton H. Werner in September 2008 and is headquartered in Atlanta, GA.

The company received FDA approval to initiate a late-stage study of IKT-001Pro for pulmonary arterial hypertension, backed by $275 million in funding. IKT-001Pro, a modified version of imatinib, aims to treat PAH with fewer side effects, leveraging Inhibikase's RAMP drug innovation engine. Risvodetinib, targeting untreated Parkinson's Disease, is in a phase 2 study with top-line data expected in Q4 2024, presenting a catalyst opportunity.

Inhibikase: Potential To Improve Current Treatment Options For PAH Patients

-- Transformative Financing worth up to $275 million from Top-Tier Institutional Healthcare Investors -- -- Advancement of IkT-001Pro into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension --

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

-- IkT-001Pro to be developed as a New Molecular Entity as the first oral, potentially disease-modifying treatment for a rapidly fatal disease primarily afflicting women between the ages of 30 and 60 -- BOSTON and ATLANTA, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Cardiopulmonary and Neurodegenerative disease through Abelson Tyrosine Kinase inhibition, today announced the closing of a private placement of approximately $110 Million from the issuance and sale of shares of the Company's common stock and accompanying warrants with potential aggregate financing of up to approximately $275 Million upon the full cash exercise of the warrants issued in the private placement, before deducting placement agent fees and offering expenses. The financing will fund execution of the Phase 2b ‘702' trial in Pulmonary Arterial Hypertension (PAH) and for general corporate purposes.

Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

-- Aggregate investment of up to approximately $275 Million by healthcare-focused investment funds, led by Soleus Capital -- BOSTON and ATLANTA, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or the “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of cardiopulmonary and neurodegenerative disease through Abelson Tyrosine Kinase inhibition, today announced the pricing of an approximately $110 million private placement financing, before deducting placement agent fees and other offering expenses. The Company intends to use the net proceeds from the private placement to finance the initiation of a Phase 2b trial in pulmonary arterial hypertension (“PAH”) and for general corporate purposes.

Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension

Inhibikase Therapeutics, Inc. (NASDAQ:IKT ) Q2 2024 Earnings Conference Call August 15, 2024 8:00 AM ET Company Participants Alexander Lobo - Precision AQ, Investor Relations Milton Werner - President and Chief Executive Officer Garth Lees-Rolfe - Chief Financial Officer Conference Call Participants Jason McCarthy - Maxim Group Edward White - H.C. Wainwright Operator Greetings and welcome to the Inhibikase Therapeutics Second Quarter 2024 Financial Results Conference Call.

Inhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call Transcript

BOSTON and ATLANTA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today reported financial results for the second quarter ended June 30, 2024 and highlighted recent developments. “The first half of 2024 has showcased the strength of our pipeline through the continued execution of key milestones for both risvodetinib (risvo) and IkT-001Pro,” said Dr. Milton H.

Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity

BOSTON and ATLANTA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it will report financial results for the second quarter ended June 30, 2024, on Wednesday, August 14, 2024, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET on Thursday, August 15, 2024, to provide a corporate update and review the financial results.

Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

BOSTON and ATLANTA, June 17, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced the company has completed enrollment in the Phase 2 ‘201' trial evaluating the safety and tolerability of risvodetinib (“risvo”), a potent selective c-Abl inhibitor, for treatment in untreated Parkinson's patients. The company expects to report trial results in the fourth quarter of 2024.

Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201' Trial Evaluating Risvodetinib in Untreated Parkinson's Disease

- Company positioning multiple assets for late-stage development across its therapeutic pipeline – BOSTON and ATLANTA, June 05, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced expansion of its therapeutic pipeline and multiple updates to its Research and Development programs. “At Inhibikase we have let fundamental scientific discoveries drive identification of new product candidates that could transform the lives of patients.

Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs

BOSTON and ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 1,672,452 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company also agreed to issue unregistered Series A warrants to purchase up to an aggregate of 1,672,452 shares of common stock, and unregistered Class B warrants to purchase up to an aggregate of 1,672,452 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold with one Series A warrant to purchase one share of common stock and one Series B warrant to purchase one share of common stock at a combined purchase price of $1.68. The Series A and Series B warrants will each have an exercise price of $1.68 per share, will be exercisable beginning on the effective date of stockholder approval and, in the case of Series A warrants, will expire on the one-year anniversary from the date of stockholder approval, and in the case of Series B warrants, will expire on the five-year anniversary from the date of stockholder approval.

Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million

Inhibikase Therapeutics, Inc. (NASDAQ:IKT ) Q1 2024 Earnings Conference Call May 16, 2024 8:00 AM ET Company Participants Alexander Lobo - Stern Investor Relations Milton Werner - CEO Garth Lees-Rolfe - CFO Conference Call Participants Ed White - H.C. Wainwright Operator Greetings and welcome to Inhibikase Therapeutics First Quarter 2024 Financial Results Conference Call.

Inhibikase Therapeutics, Inc. (IKT) Q1 2024 Earnings Call Transcript

Company to host conference call on Thursday, May 16, 2024 at 8:00 a.m. ET Company to host conference call on Thursday, May 16, 2024 at 8:00 a.m. ET

Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

BOSTON and ATLANTA, May 15, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it has filed a Request for Withdrawal with the U.S. Securities and Exchange Commission (“SEC”) with respect to the withdrawal of the Company's Registration Statement on Form S-1 (File No. 333-278844) that it filed with the SEC originally on April 19, 2024. The Registration Statement has not been declared effective by the SEC, and no securities have been sold in connection with the offering described in the Registration Statement.

Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement

- FDA indicated IkT-001Pro can be considered a New Molecular Entity and is eligible for exclusivity designations in Pulmonary Arterial Hypertension –

Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension

BOSTON and ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today issued a Letter to Shareholders.

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial Hypertension Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial Hypertension

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call Transcript

Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ET Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ET

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity

BOSTON and ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that Dr. Milton Werner, President and Chief Executive Officer of Inhibikase Therapeutics, will present an update on the of the 201 Trial evaluating risvodetinib (“risvo”) at the 2024 AD/PD Meeting being held March 5-9, 2024 in Lisbon, Portugal.

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Company to pursue eleven indications for IkT-001Pro; all previously approved for treatment with imatinib mesylate Company to pursue eleven indications for IkT-001Pro; all previously approved for treatment with imatinib mesylate

Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro

Inhibikase Therapeutics, Inc. (IKT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Here's Why Inhibikase Therapeutics, Inc. (IKT) Is a Great 'Buy the Bottom' Stock Now

ADMA Biologics

Affirm

Equitrans Midstream

Orchid Island Capital

IKT, ETRN, ADMA, AFRM and ORC have been added to the Zacks Rank #1 (Strong Buy) List on February 13, 2023.

New Strong Buy Stocks for February 13th

ACM Research

Post Holdings

POST, IKT and ACMR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 8, 2023.

Best Momentum Stocks to Buy for February 8th

Asana

Henkel AG & Co KGaA

IKT, POST, ASAN, ACMR and HENKY have been added to the Zacks Rank #1 (Strong Buy) List on February 8, 2023.

New Strong Buy Stocks for February 8th

- The Company continues to progress the 201 Trial evaluating risvodetinib in untreated Parkinson's disease - - The Company continues to progress the 201 Trial evaluating risvodetinib in untreated Parkinson's disease -

Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers

News for Inhibikase Therapeutics Stock (IKT)